Leadiant Biosciences
1
5M
1
0.02
- Areas of investment
Summary
Leadiant Biosciences is the famous Corporate Investor, which was founded in 1980. The company was established in North America in United States. The main office of represented Corporate Investor is situated in the Gaithersburg.
The usual cause for the fund is to invest in rounds with 9 partakers. The meaningful sponsors for the fund in investment in the same round are Rosalind Capital Partners, Rockmore Capital, OpusPoint Partners. In the next rounds fund is usually obtained by Third Security.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. We can highlight the next thriving fund investment areas, such as Biopharma, Biotechnology. Among the most popular portfolio startups of the fund, we may highlight Soligenix.
The increased amount of exits for fund were in 2016. The top activity for fund was in 2010. The fund is constantly included in less than 2 deals per year. The usual things for fund are deals in the range of 5 - 10 millions dollars.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Rounds per year
- 0.02
- Investments by industry
- Medical (1)
- Health Care (1)
- Biotechnology (1)
- Biopharma (1)
- Investments by region
-
- United States (1)
- Peak activity year
- 2010
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 34
- Avg. valuation at time of investment
- 30M
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.